Literature DB >> 13994348

Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis.

S C TRUELOVE, G WATKINSON, G DRAPER.   

Abstract

Entities:  

Keywords:  ADRENAL CORTEX HORMONES; COLITIS, ULCERATIVE; SULFONAMIDES

Mesh：

Substances：

Year:  1962        PMID： 13994348      PMCID： PMC1926962          DOI： 10.1136/bmj.2.5321.1708

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  8 in total

1.  Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.

Authors:  J H BARON; A M CONNELL; J E LENNARD-JONES; F A JONES
Journal:  Lancet       Date:  1962-05-26       Impact factor: 79.321

2.  An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis.

Authors:  J E LENNARD-JONES; A J LONGMORE; A C NEWELL; C W WILSON; F A JONES
Journal:  Gut       Date:  1960-09       Impact factor: 23.059

3.  Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium; a controlled trial employing restricted sequential analysis.

Authors:  G WATKINSON
Journal:  Br Med J       Date:  1958-11-01

4.  A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis.

Authors:  C G MOERTEL; J A BARGEN
Journal:  Ann Intern Med       Date:  1959-11       Impact factor: 25.391

5.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

6.  Treatment of ulcerative colitis with local hydrocortisone.

Authors:  S C TRUELOVE
Journal:  Br Med J       Date:  1956-12-01

7.  The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report.

Authors:  P S Hench; E C Kendall; C H Slocumb; H F Polley
Journal:  Ann Rheum Dis       Date:  1949-06       Impact factor: 19.103

8.  Results of treatment of ulcerative colitis with salicylazosulfapyridine.

Authors:  L M MORRISON
Journal:  Gastroenterology       Date:  1952-05       Impact factor: 22.682
  8 in total
  53 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

2.  CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

Authors:  A P DICK; M J GRAYSON; R G CARPENTER; A PETRIE
Journal:  Gut       Date:  1964-10       Impact factor: 23.059

3.  THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS.

Authors:  F C EDWARDS; S C TRUELOVE
Journal:  Gut       Date:  1963-12       Impact factor: 23.059

Review 4.  THE CONTROLLED THERAPEUTIC TRIAL IN GASTROENTEROLOGY.

Authors:  S C TRUELOVE; R WRIGHT
Journal:  Am J Dig Dis       Date:  1964-01

5.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  M J Carter; A J Lobo; S P L Travis
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

6.  Frontiers in inflammatory bowel disease. The proceedings of a conference sponsored by the McReynolds Foundation. Part 1.

Authors: 
Journal:  Am J Dig Dis       Date:  1975-06

7.  Editorial: Sulphasalazine for Crohn's diseases?

Authors: 
Journal:  Br Med J       Date:  1975-05-10

8.  Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma.

Authors:  Chris Probert
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

9.  Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease.

Authors:  Chiara De Cassan; Edoardo Savarino; Piero Marson; Tiziana Tison; Giorgia Hatem; Giacomo Carlo Sturniolo; Renata D'Incà
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  Ulcerative colitis: effect of sulphasalazine, its metabolites and indomethacin on the ability of human colonic mucosa to metabolize prostaglandins in vitro.

Authors:  K Hillier; P J Mason; S Pacheco; C L Smith
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.